SG11201808440YA - Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab - Google Patents
Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fabInfo
- Publication number
- SG11201808440YA SG11201808440YA SG11201808440YA SG11201808440YA SG11201808440YA SG 11201808440Y A SG11201808440Y A SG 11201808440YA SG 11201808440Y A SG11201808440Y A SG 11201808440YA SG 11201808440Y A SG11201808440Y A SG 11201808440YA SG 11201808440Y A SG11201808440Y A SG 11201808440YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- fully
- translationally modified
- ocular diseases
- street
- Prior art date
Links
- 208000022873 Ocular disease Diseases 0.000 title abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract 1
- 206010029113 Neovascularisation Diseases 0.000 abstract 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 244000191761 Sida cordifolia Species 0.000 abstract 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003511 endothelial effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000001525 retina Anatomy 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 229910052709 silver Inorganic materials 0.000 abstract 1
- 239000004332 silver Substances 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323285P | 2016-04-15 | 2016-04-15 | |
| US201762442802P | 2017-01-05 | 2017-01-05 | |
| US201762450438P | 2017-01-25 | 2017-01-25 | |
| US201762460428P | 2017-02-17 | 2017-02-17 | |
| PCT/US2017/027650 WO2017181021A1 (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808440YA true SG11201808440YA (en) | 2018-10-30 |
Family
ID=60041925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808440YA SG11201808440YA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| SG10202008378UA SG10202008378UA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202008378UA SG10202008378UA (en) | 2016-04-15 | 2017-04-14 | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20190127455A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3442577A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019515027A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190003556A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017250797A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3019665A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL262277A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201808440YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017181021A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| AU2017248731B2 (en) | 2016-04-15 | 2024-08-29 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| JP7685833B2 (ja) * | 2017-09-27 | 2025-05-30 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| US20210093734A1 (en) * | 2018-02-20 | 2021-04-01 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-realted macular degeneration |
| WO2019169341A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| IL313246B2 (en) * | 2018-06-28 | 2025-10-01 | Univ North Carolina Chapel Hill | Optimal cln5 expression genes and cassettes and their use |
| CN118497276A (zh) * | 2018-11-07 | 2024-08-16 | 阿库斯股份有限公司 | 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途 |
| EP3946467A1 (en) * | 2019-04-03 | 2022-02-09 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| CA3137284A1 (en) * | 2019-04-24 | 2020-10-29 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| EP4017523A4 (en) * | 2019-08-22 | 2024-01-17 | The Regents Of The University Of California | UBE3A FOR THE TREATMENT OF ANGELMAN SYNDROME |
| CN114502197A (zh) | 2019-08-26 | 2022-05-13 | 再生生物股份有限公司 | 用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变 |
| EP4041292A1 (en) | 2019-10-07 | 2022-08-17 | RegenxBio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN113952474A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| EP4225381A1 (en) | 2020-10-07 | 2023-08-16 | RegenxBio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| MX2023004035A (es) | 2020-10-07 | 2023-07-05 | Regenxbio Inc | Formulaciones para la administración supracoroidea tales como formulaciones de viscosidad alta. |
| CA3197342A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Gene therapy for ocular manifestations of cln2 disease |
| WO2022076595A1 (en) | 2020-10-07 | 2022-04-14 | Regenxbio Inc. | Formulations for suprachoroidal administration such as gel formulations |
| CA3195967A1 (en) * | 2020-10-28 | 2022-05-05 | Xu Wang | Vectorized anti-tnf-? antibodies for ocular indications |
| CA3197936A1 (en) | 2020-12-01 | 2022-06-09 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| TW202242118A (zh) * | 2020-12-18 | 2022-11-01 | 瑞士商Ａｃ 免疫有限公司 | 抗體遞送 |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| EP4314081A4 (en) * | 2021-03-31 | 2025-02-26 | Wuxi Biologics Ireland Limited | BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF |
| JP2025512962A (ja) | 2022-04-06 | 2025-04-22 | リジェネックスバイオ インコーポレイテッド | 上脈絡膜投与のための導入遺伝子をコードする発現カセットを有する組換えアデノ随伴ウイルスベクターを含む医薬組成物 |
| TW202404651A (zh) | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| TW202345913A (zh) | 2022-04-06 | 2023-12-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如凝膠調配物 |
| IL319873A (en) | 2022-09-30 | 2025-05-01 | Regenxbio Inc | Treatment of eye diseases with recombinant viral vectors containing anti-VEGF FAB |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0014945A (pt) * | 1999-10-21 | 2004-08-31 | Monsanto Co | Modificação pós-traducional de proteìnas recombinantes produzidas em plantas |
| CN1461342A (zh) * | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| NZ596837A (en) * | 2009-06-17 | 2014-02-28 | Abbvie Biotherapeutics Inc | Anti-vegf antibodies and their uses |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| MX365658B (es) * | 2014-05-13 | 2019-06-10 | Univ Pennsylvania | Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos. |
-
2017
- 2017-04-14 JP JP2019505138A patent/JP2019515027A/ja active Pending
- 2017-04-14 AU AU2017250797A patent/AU2017250797A1/en not_active Abandoned
- 2017-04-14 EP EP17783242.5A patent/EP3442577A4/en active Pending
- 2017-04-14 SG SG11201808440YA patent/SG11201808440YA/en unknown
- 2017-04-14 WO PCT/US2017/027650 patent/WO2017181021A1/en not_active Ceased
- 2017-04-14 KR KR1020187032191A patent/KR20190003556A/ko not_active Ceased
- 2017-04-14 KR KR1020237043995A patent/KR20240005973A/ko active Pending
- 2017-04-14 CA CA3019665A patent/CA3019665A1/en active Pending
- 2017-04-14 US US16/093,363 patent/US20190127455A1/en not_active Abandoned
- 2017-04-14 SG SG10202008378UA patent/SG10202008378UA/en unknown
-
2018
- 2018-10-10 IL IL262277A patent/IL262277A/en unknown
-
2019
- 2019-03-22 US US16/361,884 patent/US20190211091A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,170 patent/US20230057519A1/en not_active Abandoned
- 2022-07-06 JP JP2022108815A patent/JP2022153418A/ja active Pending
-
2024
- 2024-08-09 AU AU2024205641A patent/AU2024205641A1/en active Pending
- 2024-09-05 JP JP2024152809A patent/JP2025000642A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3019665A1 (en) | 2017-10-19 |
| US20230057519A1 (en) | 2023-02-23 |
| KR20240005973A (ko) | 2024-01-12 |
| SG10202008378UA (en) | 2020-10-29 |
| EP3442577A4 (en) | 2020-03-25 |
| IL262277A (en) | 2018-11-29 |
| US20190211091A1 (en) | 2019-07-11 |
| WO2017181021A1 (en) | 2017-10-19 |
| AU2024205641A1 (en) | 2024-09-05 |
| KR20190003556A (ko) | 2019-01-09 |
| AU2017250797A1 (en) | 2018-10-25 |
| EP3442577A1 (en) | 2019-02-20 |
| US20190127455A1 (en) | 2019-05-02 |
| JP2022153418A (ja) | 2022-10-12 |
| NZ746655A (en) | 2025-05-02 |
| JP2019515027A (ja) | 2019-06-06 |
| JP2025000642A (ja) | 2025-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808440YA (en) | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201810777WA (en) | Purification of multispecific antibodies | |
| SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201806120WA (en) | Ror1 antibody compositions and related methods | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201909656YA (en) | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201805941WA (en) | Tgfbeta 2 antibodies | |
| SG11201906670PA (en) | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
| SG11201806542PA (en) | Anti-mica antibodies | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |